Business Context and Reporting Period
Company: ProQR Therapeutics N.V.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three months ended March 31, 2018
Filing Date: May 10, 2018
Context: This filing incorporates by reference unaudited financial statements (Exhibit 99.1) and a press release (Exhibit 99.2) dated May 9, 2018, announcing results for the period.
Key Financial Metrics
The provided text serves as a cover sheet and index for the Form 6-K. It references the existence of financial statements and a press release but does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the referenced exhibits (99.1 and 99.2) which are not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that results for the three-month period ended March 31, 2018, were announced in the referenced press release.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. Such information is expected to be found in the incorporated press release (Exhibit 99.2).
Investor Verification Checklist
- Review Exhibit 99.1 for the full unaudited financial statements to obtain specific revenue, cash burn, and balance sheet data.
- Read Exhibit 99.2 (Press Release dated May 9, 2018) for management commentary, operational updates, and any guidance.
- Verify the incorporation by reference into the Company's registration statement on Form F-3 (File No. 333-207245).
- Confirm the company's status as a foreign private issuer filing under Form 20-F.